Basic Information | Post buying leads | Suppliers |
Name |
Coenzyme Q10 |
EINECS | N/A |
CAS No. | 55870-43-4 | Density | N/A |
PSA | 52.60000 | LogP | 17.85390 |
Solubility | N/A | Melting Point |
N/A |
Formula | C59H90O4 | Boiling Point | N/A |
Molecular Weight | 0 | Flash Point | N/A |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methyl-cyclohexa-2,5-diene-1,4-dione |
CAS NO.55870-43-4 has been replaced CAS NO.303-98-0
Molecular Structure:
Molecular Formula: C59H90O4
Molecular Weight: 863.3435
IUPAC Name: 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
Synonyms of Coenzyme Q10 (CAS NO.55870-43-4): 2,5-Cyclohexadiene-1,4-dione, 2-((2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl)-5,6-dimethoxy-3-methyl- ; 2,5-Cyclohexadiene-1,4-dione, 2-((2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl- ; 2,5-Cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all-E)- (9CI) ; 2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone ; p-Benzoquinone, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
CAS NO: 303-98-0
Classification Code: Drug / Therapeutic Agent ; Growth Substances ; Micronutrients ; Reproductive Effect ; Vitamins
Index of Refraction: 1.525
Molar Refractivity: 272.64 cm3
Molar Volume: 888.5 cm3
Surface Tension: 38.5 dyne/cm
Density: 0.97 g/cm3
Flash Point: 324.5 °C
Enthalpy of Vaporization: 126.29 kJ/mol
Boiling Point: 869 °C at 760 mmHg
Vapour Pressure: 1.23E-30 mmHg at 25°C
In 1957 Coenzyme Q10 (CAS NO.55870-43-4) was first discovered by professor Andrew L. Crane and colleagues at the University of Wisconsin-Madison Enzyme Institute.
In 1958, its chemical structure was reported by Dr. Karl Folkers and coworkers at Merck.
Coenzyme Q10 (CAS NO.55870-43-4) is used as a dietary supplement. Coenzyme antioxidant benefits to the brain is also studied for the treatment of neurodegenerative disease.
The benzoquinone portion of Coenzyme Q10 (CAS NO.55870-43-4) is synthesized from tyrosine, whereas the Isoprene sidechain is synthesized from acetyl-CoA through the mevalonate pathway.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD | intramuscular | > 500mg/kg (500mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |
mouse | LD | intravenous | > 500mg/kg (500mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |
mouse | LD | oral | > 4gm/kg (4000mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |
mouse | LD | subcutaneous | > 500mg/kg (500mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |
rat | LD | intramuscular | > 500mg/kg (500mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |
rat | LD | intravenous | > 250mg/kg (250mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |
rat | LD | oral | > 4gm/kg (4000mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |
rat | LD | subcutaneous | > 500mg/kg (500mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 769, 1972. |